ClinicalTrials.gg
CompletedNCT00191646Updated Mar 4, 2011Results posted

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

A Phase 3 interventional study of Gemcitabine and Paclitaxel in Genital Neoplasms, Female, Fallopian Tube Neoplasms and Ovarian Neoplasms, sponsored by Eli Lilly and Company. Completed at 55 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-04.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
919
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 37 studies in Genital Neoplasms, Female with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Genital Neoplasms, Female · United States.

Enrollment
2nd of 33
919 · median 40
Started
2002
with 1 other
Phase 3
2 of 37
none open now
Registered
2nd of 37
by date
Lead sponsor
4 of 37
Eli Lilly and Company

Among the 37 studies in Genital Neoplasms, Female with a site in United States, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2002, is one of 2 in phase 3, and was the 2nd registered.

Genital Neoplasms, Female

81 studies on the registry are indexed under Genital Neoplasms, Female; 18 are open to participants now.

Browse Genital Neoplasms, Female studies →

Open to participants now

6 of the 37 studies in Genital Neoplasms, Female with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Genital Neoplasms, Female studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Genital Neoplasms, Female with a site in United States, or all of them as a file.
02

Study summary

This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. Patients with disease after induction therapy will crossover to receive single agent therapy.

Read the detailed description

This study (Study B9E-US-S302) is a multicenter, comparative, open-label randomized, superiority, trial evaluating Gemcitabine and Carboplatin to the standard of care. Both treatment arms will be given the option to receive elective consolidation therapy of Paclitaxel 135 mg/m\^2 given every 28 days for one year. Patients not achieving a complete response will crossover to the opposite single agent.

03

Conditions studied

  • Genital Neoplasms, Female
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Pelvic Neoplasms
  • Peritoneal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with a histologic diagnosis of primary peritoneal carcinoma, epithelial ovarian carcinoma or fallopian tube carcinoma Stage IC, II, III or IV.
  • All patients must have had surgery for fallopian, ovarian or peritoneal carcinoma to establish the diagnosis and have tissue available for histologic evaluation and confirmation of organ of origin.
  • Patients must be enrolled no more than twelve weeks postoperatively.
  • Patients must be willing to receive their chemotherapy drugs intravenously, as intraperitoneal therapy is not part of this trial.

Key Exclusion Criteria:

  • Patients with a current diagnosis of epithelial ovarian tumor of low malignant potential (Borderline carcinomas) are not eligible.
  • Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
  • Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded
  • With the exception of non-melanoma skin cancer and other specific patients who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy are excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
919 participants (actual)

Study arms

  • Experimental
    Gemcitabine/Carboplatin

    Gemcitabine 1000 milligrams per meter square (mg/m\^2) Day 1 and Day 8, Carboplatin Area Under the Curve (AUC) 5 Day 1, six 21-day cycles

    Drug: Gemcitabine · Drug: Carboplatin

  • Active comparator
    Paclitaxel/Carboplatin

    Paclitaxel 175 milligrams per meter square (mg/m\^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles

    Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • 1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity

    Also known as: LY188011, Gemzar

  • 175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year) If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity

  • Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.

    Time frame: Baseline to measured progressive disease or death up to 82 months

Secondary outcomes

  1. Proportion of Participants With Response (Response Rate)

    Response rate (RR) = proportion of participants with best overall Complete Response (CR: disappearance of all target lesions \[TL\]) or Partial Response (PR: 30% decrease in sum of longest diameter of TL). Induction therapy RR = number of participants with CR or PR during induction divided by number of participants with measurable disease at baseline (TL measurement during screening). Crossover therapy RR = number of participants with CR or PR during crossover divided by number of participants with measurable disease at baseline (latest TL measurement by first dose date of crossover therapy).

    Time frame: Baseline to measured progressive disease up to 82 months

  2. Time to Treatment Failure

    Time to treatment failure was defined as the duration from date of randomization to the date of the first of the following events: early discontinuation of study therapy; progression of disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for participants who did not discontinue early, who are still alive, and who have not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.

    Time frame: Baseline to stopping treatment up to 82 months

  3. Overall Survival

    Overall survival is defined as the duration from baseline to death. For participants who are still alive at the data cut-off date, survival will be censored at the last contact date. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.

    Time frame: Baseline to death from any cause up to 82 months

07

Results

Posted Sep 9, 2010
Limitations and caveats
Trial was designed with overall survival as primary endpoint. Enrollment was slower than expected. After 4 years, 919 patients were randomized and in August 2006, protocol was amended: primary endpoint was changed to progression free survival (PFS).

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine/CarboplatinPaclitaxel/Carboplatin
Started417414
Received induction therapy411409
Received consolidation therapy169183
Received crossover therapy7778
Completed246261
Not completed171153
Withdrew: Toxicity2637
Withdrew: Disease progression56
Withdrew: Physician decision2011
Withdrew: Withdrawal by subject5839
Withdrew: Protocol violation57
Withdrew: Death68
Withdrew: Other3334
Withdrew: Missing data1811

Outcome measures

PrimaryProgression Free Survival (PFS)

Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.

Time frame:
Baseline to measured progressive disease or death up to 82 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsGemcitabine/CarboplatinPaclitaxel/Carboplatin
Progression Free Survival (PFS)20.0 (17.9 to 22.2)22.2 (19.0 to 25.7)
Statistical analysis
  • Gemcitabine/Carboplatin vs Paclitaxel/Carboplatin · Log Rank · p = 0.199
SecondaryProportion of Participants With Response (Response Rate)

Response rate (RR) = proportion of participants with best overall Complete Response (CR: disappearance of all target lesions \[TL\]) or Partial Response (PR: 30% decrease in sum of longest diameter of TL). Induction therapy RR = number of participants with CR or PR during induction divided by number of participants with measurable disease at baseline (TL measurement during screening). Crossover therapy RR = number of participants with CR or PR during crossover divided by number of participants with measurable disease at baseline (latest TL measurement by first dose date of crossover therapy).

Time frame:
Baseline to measured progressive disease up to 82 months
Reported as:
Mean · proportion of responders
Proportion of Participants With Response (Response Rate)
proportion of respondersGemcitabine/Carboplatin (Induction)Paclitaxel/Carboplatin (Induction)Gemcitabine (Crossover)Paclitaxel (Crossover)
Proportion of Participants With Response (Response Rate)0.676 (0.638 to 0.798)0.711 (0.651 to 0.822)0.357 (0.194 to 0.576)0.303 (0.161 to 0.500)
Statistical analysis
  • Gemcitabine/Carboplatin (Induction) vs Paclitaxel/Carboplatin (Induction) · Fisher Exact · p = 0.771
  • Gemcitabine (Crossover) vs Paclitaxel (Crossover) · Fisher Exact · p = 0.784
SecondaryTime to Treatment Failure

Time to treatment failure was defined as the duration from date of randomization to the date of the first of the following events: early discontinuation of study therapy; progression of disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for participants who did not discontinue early, who are still alive, and who have not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.

Time frame:
Baseline to stopping treatment up to 82 months
Reported as:
Median · months
Time to Treatment Failure
monthsGemcitabine/CarboplatinPaclitaxel/Carboplatin
Time to Treatment Failure13.0 (11.7 to 15.1)13.1 (11.4 to 14.3)
Statistical analysis
  • Gemcitabine/Carboplatin vs Paclitaxel/Carboplatin · Log Rank · p = 0.621
SecondaryOverall Survival

Overall survival is defined as the duration from baseline to death. For participants who are still alive at the data cut-off date, survival will be censored at the last contact date. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.

Time frame:
Baseline to death from any cause up to 82 months
Reported as:
Median · months
Overall Survival
monthsGemcitabine/CarboplatinPaclitaxel/Carboplatin
Overall Survival43.8 (38.8 to 48.4)57.3 (48.5 to 64.0)
Statistical analysis
  • Gemcitabine/Carboplatin vs Paclitaxel/Carboplatin · Log Rank · p = 0.013

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine/Carboplatin Induction—96/412 (23.3%)404/412 (98.1%)
Paclitaxel/Carboplatin Induction—72/408 (17.6%)394/408 (96.6%)
Consolidation (Gemcitabine to Paclitaxel)—14/169 (8.3%)157/169 (92.9%)
Consolidation (Paclitaxel to Paclitaxel)—12/183 (6.6%)170/183 (92.9%)
Crossover (Paclitaxel to Gemcitabine)—8/78 (10.3%)76/78 (97.4%)
Crossover (Gemcitabine to Paclitaxel)—8/77 (10.4%)73/77 (94.8%)
Most frequent serious events
Showing 10 of 159
Most frequent serious events
EventGemcitabine/Carboplatin InductionPaclitaxel/Carboplatin InductionConsolidation (Gemcitabine to Paclitaxel)Consolidation (Paclitaxel to Paclitaxel)Crossover (Paclitaxel to Gemcitabine)Crossover (Gemcitabine to Paclitaxel)
PlateletsInvestigations43/4125/4080/1690/1830/780/77
HemoglobinInvestigations24/4123/4080/1690/1831/780/77
Absolute neutrophil count/absolute granulocyte countInvestigations21/41214/4081/1691/1831/780/77
NauseaGastrointestinal disorders12/4128/4080/1690/1830/780/77
PyrexiaGeneral disorders8/4122/4080/1690/1832/781/77
VomitingGastrointestinal disorders10/4129/4081/1690/1831/780/77
White blood cellsInvestigations10/4123/4080/1691/1830/780/77
Febrile neutropeniaBlood and lymphatic system disorders5/4129/4080/1690/1831/781/77
DehydrationMetabolism and nutrition disorders6/4127/4080/1690/1831/780/77
Abdominal painGastrointestinal disorders6/4125/4081/1692/1830/780/77
Most frequent other events
Showing 10 of 86
Most frequent other events
EventGemcitabine/Carboplatin InductionPaclitaxel/Carboplatin InductionConsolidation (Gemcitabine to Paclitaxel)Consolidation (Paclitaxel to Paclitaxel)Crossover (Paclitaxel to Gemcitabine)Crossover (Gemcitabine to Paclitaxel)
HemoglobinInvestigations385/412352/40883/169103/18366/7854/77
White blood cellsInvestigations380/412350/40888/169101/18368/7849/77
PlateletsInvestigations379/412233/40836/16923/18361/7816/77
Anc/agcInvestigations378/412361/40888/16993/18368/7847/77
FatigueGeneral disorders281/412279/408108/169119/18356/7840/77
AlopeciaSkin and subcutaneous tissue disorders94/412249/408102/16994/18342/7849/77
NauseaGastrointestinal disorders213/412205/40867/16946/18332/7821/77
ConstipationGastrointestinal disorders173/412170/40854/16962/18331/7825/77
ArthralgiaMusculoskeletal and connective tissue disorders48/412108/40866/16953/18316/7825/77
Neuropathy peripheralNervous system disorders22/41299/40862/16968/18317/7823/77

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine/CarboplatinPaclitaxel/CarboplatinTotal
Mean59.7 ± 11.460.3 ± 10.860.0 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine/CarboplatinPaclitaxel/CarboplatinTotal
Female417414831
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Gemcitabine/CarboplatinPaclitaxel/CarboplatinTotal
Caucasian379379758
Black or African American121325
Asian5510
Native American213
Other191635
Organ of Origin
Organ of Origin(participants)Gemcitabine/CarboplatinPaclitaxel/CarboplatinTotal
Ovary355362717
Peritoneum5650106
Missing Data628
Extent of Residual Disease
Extent of Residual Disease(participants)Gemcitabine/CarboplatinPaclitaxel/CarboplatinTotal
Measurable139114253
Non-measurable276300576
Missing Data202
Zubrod Performance Status
Zubrod Performance Status(participants)Gemcitabine/CarboplatinPaclitaxel/CarboplatinTotal
0239232471
1139157296
2271643
>= 3000
Missing Data12921
International Federation of Gynecology and Obstetrics (FIGO) Stage at Initial Surgery
International Federation of Gynecology and Obstetrics (FIGO) Stage at Initial Surgery(participants)Gemcitabine/CarboplatinPaclitaxel/CarboplatinTotal
Stage Ic212243
Stage II443983
Stage III284289573
Stage IV6863131
Missing Data011
Histology
Histology(participants)Gemcitabine/CarboplatinPaclitaxel/CarboplatinTotal
Mucinous101020
Serous283276559
Endometroid444084
Undifferentiated7714
Clear Cell212344
Mixed Epithelial91322
Transitional Cell314
Malignant Brenner's Tumor000
Adenocarcinoma Not Otherwise Specified (NOS)222345
Other172138
Missing Data101

2 further baseline measures are reported on the registry.

08

Study locations

55 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85006, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Little Rock, Arkansas 72205, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Los Gatos, California 95032, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Modesto, California 95350, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92121, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Englewood, Colorado 80113, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newark, Delaware 19713, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Myers, Florida 33901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Miami, Florida 33143, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sunrise, Florida 33323, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30342, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Savannah, Georgia 31404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palatine, Illinois 60067, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46260, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Bend, Indiana 46617, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Metairie, Louisiana 70006, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Orleans, Louisiana 70121, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Scarborough, Maine 04074, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Detroit, Michigan 48201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grand Rapids, Michigan 49546, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Duluth, Minnesota 55805, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Minneapolis, Minnesota 55455, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, Minnesota 55905, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kansas City, Missouri 64111, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Billings, Montana 59107, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reno, Nevada 89502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hackensack, New Jersey 07601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14620, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chapel Hill, North Carolina 27599, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charlotte, North Carolina 28204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durham, North Carolina 27710, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenville, North Carolina 27858, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbus, Ohio 43222, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dayton, Ohio 45429, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73112, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dunmore, Pennsylvania 18512, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Johnstown, Pennsylvania 15905, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pittsburgh, Pennsylvania 15224, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sayre, Pennsylvania 18840, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Providence, Rhode Island 02905, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina 29425, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, South Carolina 29210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenville, South Carolina 29601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chattanooga, Tennessee 37404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37920, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38120, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78735, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lubbock, Texas 79410, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Roanoke, Virginia 24014, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madison, Wisconsin 53792, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 009362712, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Oct 2002
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Sep 9, 2010
Last update
Mar 4, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191646
First posted
Sep 19, 2005
Start date
Oct 2002
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Sep 9, 2010
Last update
Mar 4, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) OR 1-317-615-4559 MON-FRI 9AM -5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion